<DOC>
	<DOCNO>NCT00084552</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Intensity-modulated radiation therapy ( radiation direct tumor precisely standard radiation therapy ) may reduce damage healthy tissue near tumor . It yet know whether reduce dose radiation erectile tissue help prevent erectile dysfunction . PURPOSE : This randomized phase III trial study intensity-modulated radiation therapy alone see well work compare intensity-modulated radiation therapy reduce dos erectile tissue treat patient stage II prostate cancer .</brief_summary>
	<brief_title>Intensity-Modulated Radiation Therapy With Without Decreased Radiation Dose Erectile Tissue Treating Patients With Stage II Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare erectile dysfunction patient stage T1b-T2c adenocarcinoma prostate treatment intensity-modulated radiotherapy v without dose spar erectile tissue . Secondary - Compare biochemical freedom failure rate , measure prostate cancer control , patient treat regimen . - Compare quality life patient treat regimen . - Determine association molecular marker biochemical freedom failure rate endpoint patient treat regimen . OUTLINE : This randomize , single-blind study . Patients stratify accord age ( ≤ 65 v &gt; 65 ) , prescription radiotherapy dose ( 74 Gy v 76 Gy ) , frequency erection sexual activity within past 4 week ( time vs sometimes vs time always ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo conventional intensity-modulated radiotherapy ( IMRT ) daily 5 day week approximately 7.5 week . - Arm II : Patients undergo IMRT dose restriction erectile tissue daily 5 day week approximately 7.5 week . Treatment arm continue absence unacceptable toxicity disease metastasis . Quality life assess baseline , 6 12 month , annually 4 year Patients follow 3 month every 6 month thereafter . PROJECTED ACCRUAL : A total 200 patient ( 100 per treatment arm ) accrue study within 2.5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Clinical stage T1bT2c palpation Pretreatment prostatespecific antigen ≤ 20 ng/mL Gleason score ≤ 7 Suitable erectile function , define response ≥ score 2 question # 1 International Index Erectile Function Questionnaire No clinical , radiographic , pathologic evidence nodal distant metastatic disease PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Fertile patient must use effective contraception No active malignancy within past 5 year except nonmetastatic skin cancer earlystage chronic lymphocytic leukemia ( welldifferentiated small cell lymphocytic lymphoma ) No medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Prior androgenablation therapy allow provided total calculated duration ≤ 4 month Radiotherapy No prior pelvic radiotherapy Surgery No prior plan radical prostate surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>sexual dysfunction</keyword>
	<keyword>sexuality reproductive issue</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>